These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 20949566)

  • 1. Optimizing thiopurine therapy in inflammatory bowel disease.
    Chevaux JB; Peyrin-Biroulet L; Sparrow MP
    Inflamm Bowel Dis; 2011 Jun; 17(6):1428-35. PubMed ID: 20949566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
    Kiszka-Kanowitz M; Theede K; Nielsen AM
    Ugeskr Laeger; 2014 May; 176(22):. PubMed ID: 25352005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.
    Leong RW; Gearry RB; Sparrow MP
    Expert Opin Drug Saf; 2008 Sep; 7(5):607-16. PubMed ID: 18759713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.
    Amin J; Huang B; Yoon J; Shih DQ
    Inflamm Bowel Dis; 2015 Feb; 21(2):445-52. PubMed ID: 25248004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing the therapeutic potential of azathioprine/6-mercaptopurine in the treatment of inflammatory bowel disease.
    Papadakis KA
    J Clin Gastroenterol; 2003; 36(5):379-81. PubMed ID: 12702974
    [No Abstract]   [Full Text] [Related]  

  • 6. Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease.
    Seinen ML; van Nieuw Amerongen GP; de Boer NK; Mulder CJ; van Bezu J; van Bodegraven AA
    Ther Drug Monit; 2016 Oct; 38(5):621-7. PubMed ID: 27465973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
    Haines ML; Ajlouni Y; Irving PM; Sparrow MP; Rose R; Gearry RB; Gibson PR
    Inflamm Bowel Dis; 2011 Jun; 17(6):1301-7. PubMed ID: 20812329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease.
    Bradford K; Shih DQ
    World J Gastroenterol; 2011 Oct; 17(37):4166-73. PubMed ID: 22072847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.
    Dubinsky MC; Yang H; Hassard PV; Seidman EG; Kam LY; Abreu MT; Targan SR; Vasiliauskas EA
    Gastroenterology; 2002 Apr; 122(4):904-15. PubMed ID: 11910342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of thiopurine metabolite monitoring in inflammatory bowel disease.
    Beswick L; Friedman AB; Sparrow MP
    Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):383-92. PubMed ID: 24684593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
    Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of azathioprine/6-mercaptopurine treatment in children with IBD is not necessary.
    Griffiths AM
    Inflamm Bowel Dis; 2003 Nov; 9(6):389-91; discussion 392-3. PubMed ID: 14671489
    [No Abstract]   [Full Text] [Related]  

  • 13. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
    Kiszka-Kanowitz M; Theede K; Nielsen AM
    Ugeskr Laeger; 2015 Jun; 177(26):1253-5. PubMed ID: 26550625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication?
    Meijer B; Seinen ML; van Egmond R; Bouma G; Mulder CJJ; van Bodegraven AA; de Boer NKH
    Inflamm Bowel Dis; 2017 Nov; 23(11):2011-2017. PubMed ID: 28617756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD.
    van Gennep S; Konté K; Meijer B; Heymans MW; D'Haens GR; Löwenberg M; de Boer NKH
    Aliment Pharmacol Ther; 2019 Sep; 50(5):484-506. PubMed ID: 31342537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
    Jharap B; de Boer NK; Stokkers P; Hommes DW; Oldenburg B; Dijkstra G; van der Woude CJ; de Jong DJ; Mulder CJ; van Elburg RM; van Bodegraven AA;
    Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of Immunomodulators and Biologic Agents on Malignancy in Patients with Inflammatory Bowel Disease].
    Kim JH; Kim JW
    Korean J Gastroenterol; 2017 Oct; 70(4):162-168. PubMed ID: 29060953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.
    Teml A; Schaeffeler E; Herrlinger KR; Klotz U; Schwab M
    Clin Pharmacokinet; 2007; 46(3):187-208. PubMed ID: 17328579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing immunomodulator therapy for inflammatory bowel disease.
    Dubinsky MC
    Curr Gastroenterol Rep; 2003 Dec; 5(6):506-11. PubMed ID: 14602061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety.
    Dubinsky MC
    Clin Gastroenterol Hepatol; 2004 Sep; 2(9):731-43. PubMed ID: 15354273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.